Transplantation Medicine. |Kidney Allograft Rejection Monitoring.

End-stage renal disease (ESRD) occurs when the kidneys lose their ability to filter the blood and remove harmful substances through the production of urine. 
Loss of this function results in hemodynamic changes and accumulation of metabolic waste, leading to high blood pressure, uremia and kidney failure. 
When a patient loses about 90% of kidney function, dialysis is the next step. If dialysis stops working effectively, kidney transplantation is needed. 

Kidney transplantation improves quality of life, but also includes a number of health risks, including rejection of the donor kidney. Rejection is very serious, and clinicians work very hard to preserve the transplanted kidney.

Currently, lacking clear rejection-associated biomarkers, a biopsy is required with histological analysis to assess whether the kidney is in the process of being rejected.

In contrast, close monitoring of metabolic biomarkers for kidney rejection offers opportunities for early intervention and may decrease the number of biopsies required to assess the new kidney function. 


*US National Institute of Diabetes and Digestive and Kidney Diseases 

AXINON® renalTX-SCORE®-U100. |Non-Invasive Kidney Allograft Surveillance.

Advanced. Automated. Affordable.

AXINON® renalTX-SCORE®-U100 is a CE-marked urine test using metabolomics and Magnetic Group Signaling (MGS®) technology to support clinical decision making in the context of kidney transplant rejection. This non-invasive test analyzes and evaluates a validated metabolite biomarker constellation.

The AXINON® renalTX-SCORE®-U100 allows for close kidney allograft health surveillance. It is non-invasive and suitable for outpatient monitoring to improve patient compliance. The test also decreases the need for an invasive, painful biopsy. During transplantation follow-up care, AXINON® renalTX-SCORE®-U100 can provide information on non-specific symptoms by distinguishing graft rejection reactions.


Go to FAQs

Technology. |The AXINON® System.

Easy. Fast. Efficient.

Nuclear magnetic resonance (NMR) spectroscopy is a proven and highly accurate test technology that assesses a variety of compounds at a molecular level.

Our AXINON® System, using FDA-cleared technology, is the core platform we use to develop diagnostic tests for illnesses stemming from metabolic dysfunction, including chronic heart, kidney and liver diseases.

This system incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy for precise results.

To date, more than 3.5 million tests have been performed worldwide using Numares technology.

Go to Technology


* For Research Use only in the United States. Numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.

You did not activate the necessary cookies for this content.

activate necessary cookies and show content